Shay Capital’s Lifecore Biomedical LFCR Stock Holding History

Shay Capital’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-15,000	Closed	-$145K	–	430
2023 Q2	$145K	Buy	+15,000	New	+$91.6K	0.02%	310

Other funds holding LFCR

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

325 Capital New York $274M AUM 49.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Shay Capital's LFCR Position: Q4 2024 in Review

Shay Capital sold out of Lifecore Biomedical (LFCR) in Q4 2024, closing a stake of 23,000 shares — an estimated $113K sold.

Shay Capital first reported a position in LFCR in Q4 2023 and held it in 2 quarters. The position peaked at $113K in Q3 2024. 77 funds tracked by Wall St. Rank hold LFCR as of Q4 2024.

Shay Capital reported no remaining Lifecore Biomedical position as of Q4 2024 after selling out during the quarter.
Shay Capital sold 23,000 Lifecore Biomedical shares in Q4 2024, an estimated $113K.
Shay Capital first reported a position in Lifecore Biomedical in Q4 2023 and held it in 2 quarters.
Shay Capital's Lifecore Biomedical position peaked at $113K in Q3 2024.
77 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2024.

Based on Shay Capital's 13F filing for Q4 2024, filed 14 Feb 2025.